健脾益肾汤联合化疗对晚期胃癌患者免疫功能的影响  

Effect of jianpi yishen decoction combined with chemotherapy on immune function in patients with advanced gastric cancer

作　　者：张峥祥 高龙 徐文江[3] 赵静宜 ZHANG Zhengxiang;GAO Long;XU Wenjiang;ZHAO Jingyi(Department of Spleen,Stomach and Liver Diseases,Baoji Hospital of Traditional Chinese Medicine,Baoji 721000,Shaanxi,China;Department of Emergency,Baoji Hospital of Traditional Chinese Medicine,Baoji 721000,Shaanxi,China;Department of Oncology and Hematology,Baoji Hospital of Traditional Chinese Medicine,Baoji 721000,Shaanxi,China;Department of Surgery,Baoji Hospital of Traditional Chinese Medicine,Baoji 721000,Shaanxi,China)

机构地区：[1]宝鸡市中医医院脾胃肝病科,陕西宝鸡7210000 [2]宝鸡市中医医院急诊科,陕西宝鸡7210000 [3]宝鸡市中医医院肿瘤血液科,陕西宝鸡7210000 [4]宝鸡市中医医院外科,陕西宝鸡7210000

出　　处：《癌症进展》2022年第19期2022-2025,共4页Oncology Progress

摘　　要：目的探讨健脾益肾汤联合化疗对晚期胃癌患者免疫功能的影响。方法依据治疗方式的不同将60例晚期胃癌患者分为对照组和观察组,每组30例,对照组患者给予奥沙利铂+亚叶酸钙+5-氟尿嘧啶(FOLFOX4)方案化疗,观察组患者给予FOLFOX4方案化疗联合健脾益肾汤治疗。比较两组患者的临床疗效、免疫功能指标(包括CD3^(+)、CD4^(+)、CD8^(+),计算CD4^(+)/CD8^(+))、生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)]和不良反应发生情况。结果观察组患者的治疗总有效率为63.33%,高于对照组患者的36.67%,差异有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于本组治疗前,CD8^(+)水平均低于本组治疗前,且观察组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者EORTCQLQ-C30量表各维度评分及总分均高于本组治疗前,且观察组患者EORTCQLQ-C30量表各维度评分及总分均高于对照组,差异均有统计学意义(P﹤0.05)。观察组患者恶心呕吐、腹泻、外周神经毒性、手足综合征发生率均低于对照组,差异均有统计学意义(P﹤0.05)。结论健脾益肾汤联合化疗可提高晚期胃癌患者的临床疗效,调节患者机体免疫功能,降低不良反应发生率,提高生活质量。Objective To investigate the effect of jianpi yishen decoction combined with chemotherapy on immune function in patients with advanced gastric cancer. Method A total of 60 patients with advanced gastric cancer were divided into control group and observation group according to different treatment methods, with 30 cases in each group. The patients in the control group were treated with oxaliplatin+calcium folinate+5-fluorouracil(FOLFOX4) regimen chemotherapy, while the patients in the observation group were treated with FOLFOX4 regimen chemotherapy combined with jianpi yishen decoction. The clinical efficacy, immune function indicators(CD3, CD4, CD8, CD4/CD8), quality of life[European Organization for Research and Treatment of Cancer quality of life questionnaire core-30(EORTC QLQ-C30)],and adverse events were compared between the two groups. Result The objective effective rate of treatment in the observation group was 63.33%, which was higher than 36.67% in the control group, and the difference was statistically significant(P<0.05). After the treatment, the levels of CD3, CD4, and CD4/CD8in the two groups were higher than those before treatment, while the levels of CD8were lower than those before the treatment, the levels of CD3, CD4and CD4/CD8in the observation group were higher than those in the control group, and the level of CD8was lower than that of the control group, and the differences were statistically significant(P<0.05). After the treatment, the scores of each dimension and total score of EORTC QLQ-C30 scale in the two groups were higher than those before treatment, and the scores of each dimension and total score of EORTC QLQ-C30 scale of patients in the observation group were higher than those in the control group, and the differences were statistically significant(P<0.05). The incidences of nausea and vomiting, diarrhea, peripheral neurotoxicity, and hand-foot syndrome in the observation group were lower than those in the control group, and the differences were statistically significant(P< 0.05). Con

关 键 词：胃癌 健脾益肾汤 化疗 免疫功能 

分 类 号：R735.2[医药卫生—肿瘤]